Decoding clinical trial jargon: helping people understand theefficacy end points used in cancer trials
People living with cancer should have access to clear and comprehensible treatment information to empower informed decision-making. With the increasing adoption of open access publishing and plain-language summaries, clinical trial findings in journals are becoming more accessible. However, this will only help patients if they are equipped with the relevant knowledge and understanding to make sense of these findings. This podcast highlights the need to support this aspect of health literacy by bringing together the perspectives of a patient, a patient advocate and a medical oncologist. It is accompanied by two visual, plain-language guides designed to help general audiences understand the key efficacy end points that are commonly used in trials of solid tumor treatments.
Authors
- Eric Kumar Singhi (ORCID: https://orcid.org/0000-0001-5918-9168)
- Hannah FitzGibbon (ORCID: https://orcid.org/0000-0002-4897-167X)
- Gissoo DeCotiis
- Michael V. Henley
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Daiichi Sankyo (Germany) (DE)
- China Institute Of Communications (CN)
- Daiichi-Sankyo (South Korea) (KR)
- Daiichi Sankyo (United States) (US)
- National Patient Safety Foundation (US)
Publication Details
- Journal
- Future Oncology
- Published
- 2024-12-18
- DOI
- https://doi.org/10.1080/14796694.2024.2433411
- Citations
- 1
- Primary Topic
- Ethics in Clinical Research
- Type
- article
- Field-Weighted Citation Impact
- 0.54
Funders
- Daiichi Sankyo Europe